MACROGENICS INC (MGNX)
A
Pipeline Grade
Financial Position (from SEC Filings)
$66.5M
Cash & Equivalents
$35.8M
Quarterly Burn Rate
6 mo
Est. Cash Runway
$275M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (1 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
MARGETUXIMAB-CMKB
MARGENZA |
APPROVED | Acute Flaccid Paralysis, Acute Myeloid Leukemia, Advanced Breast Cancer, Advanced Cancer, Advanced Solid Tumor, Advanced Solid Tumor, Adult, Advanced Solid Tumors, AML, AML, Adult Recurrent, Anal Cancer, Anal Neoplasm, Androgen-Independent Prostatic Cancer, Androgen-Independent Prostatic Neoplasms, Androgen-Insensitive Prostatic Cance, Androgen-Insensitive Prostatic Cancer, Androgen-Resistant Prostatic Cancer, Bladder Cancer, Blastic Plasmacytoid Dendritic Cell Neoplasm, Breast Cancer, Cancer, Carcinoma, Squamous Cell of Head and Neck, Castration-Resistant Prostatic Cancer, Cervical Cancer, Cholangiocarcinoma, Chronic Myeloid Leukemia, Classical Hodgkin Lymphoma, Clear Cell Adenocarcinoma of Cervix, Clear Cell Adenocarcinoma of Fallopian Tube, Clear Cell Adenocarcinoma of Ovary, Clear Cell Adenocarcinoma of Peritoneum, Clear Cell Adenocarcinoma of Uterus, Clear Cell Adenocarcinoma of Vagina, Clear Cell Adenocarcinoma of Vulva, Clear Cell Renal Cell Carcinoma, Colon Cancer, Colorectal Cancer, Colorectal Cancer |
Upcoming Catalysts
No upcoming catalysts detected for this company.